We would love for you to become a part of our community. Join our Discord to connect with us and other members!

Ticker
COLO-B.CO

Price
801.00
Stock movement down
-15.20 (-1.86%)
Company name
Coloplast A/S
Exchange
(CO
,
Currency
DKK
)
Sector
Healthcare >
Medical Instruments & Supplies
capitalizzazione di mercato
166.08B
Inserire valore
195.42B
Prezzo/Vendite
6.14
Prezzo/Libro contabile
9.26
Rendimento dei dividendi
-
Crescita dei dividendi
-
Anni di crescita
-
Pagamento FCF
320.65%
P/E finale
32.87
P/E futuro
29.38
PEG
-
Crescita dell'EPS
4.33%
Profitto dopo 1 anno
2.46%
Profitto dopo 3 anni
-9.91%
Profitto dopo 5 anni
0.35%
Profitto dopo 10 anni
4.56%
Ultimo aggiornamento: 2024-12-19

DIVIDENDI

COLO-B.CO non paga dividendi

VALUTAZIONE

Rapporti di valutazione

Loading...
Dati sui rapporti di valutazione
P/E finale32.87
Prezzo a OCF60.04
Prezzo a FCF112.82
Prezzo rispetto al MOL38.14
Rapporto EV EBITDA44.88

Valutazione (vendite/valore contabile)

Loading...
Dati di valutazione (vendite/valore contabile).
Prezzo alle vendite6.14
Prezzo al valore contabile9.26
EV alle vendite7.23

FINANZIARIE

Per azione

Loading...
Dati per azione
Conteggio azioni attuali207.34M
EPS (TTM)22.45
FCF per azione (TTM)6.54

Conto economico

Loading...
Dati sul conto economico
Entrate (TTM)27.03B
Profitto lordo (TTM)18.27B
Guadagno operativo (TTM)7.37B
Utile netto (TTM)5.05B
EPS (TTM)22.45
EPS (1 anno in avanti)27.26

Margini

Loading...
Dati sui margini
Margine lordo (TTM)67.59%
Margine operativo (TTM)27.25%
Margine di profitto (TTM)18.69%

Bilancio

Loading...
Crea un account gratuito o accedi per vedere questo grafico
Dati di bilancio
Contanti788.00M
Crediti netti4.67B
Totale dei beni attuali10.44B
Avviamento19.38B
Beni immateriali10.96B
Immobili, impianti e macchinari13.27B
Totale dei beni48.07B
Debiti1.52B
Debito a lungo/breve termine22.63B
Totale passività correnti10.20B
passività totali30.13B
Patrimonio dell'azionista17.94B
Beni tangibili netti0.00

Flusso di cassa

Loading...
Crea un account gratuito o accedi per vedere questo grafico
Dati di flusso di cassa
Flusso di cassa operativo (TTM)2.77B
Spese in conto capitale (TTM)1.29B
Flusso di cassa libero (TTM)1.47B
Dividendi pagati (TTM)4.72B

Ritorni finanziari

Loading...
Crea un account gratuito o accedi per vedere questo grafico
Dati sui rendimenti finanziari
Ritorno sul capitale28.16%
Rendimento sui beni10.51%
Ritorno sul capitale investito12.60%
Rendimento in contanti sul capitale investito3.67%

INFORMAZIONI SUI TITOLI

Grafico azionario

Loading...
Dati sui prezzi delle azioni
Aperto815.60
Massimo giornaliero819.40
Minimo giornaliero799.40
Volume giornaliero335K
Massimo storico1182.50
Stima dell'analista a 1 anno926.10
Beta0.34
EPS (TTM)22.45
Dividendi per azione-
Dati ex dividendo6 Dec 2024
Prossima data di guadagno4 Feb 2025

Potenziale al ribasso

Loading...
Dati potenziali al ribasso
COLO-B.COS&P500
Attuale calo dei prezzi dal massimo storico-32.26%-3.54%
Maggior calo di prezzo-43.67%-56.47%
Data del calo più alto28 Oct 19949 Mar 2009
Calo medio dal valore più alto-11.73%-11.13%
Tempo medio per il nuovo massimo16 days12 days
Tempo massimo per il nuovo massimo852 days1805 days
DETTAGLI DELLA società
COLO-B.CO (Coloplast A/S) company logo
Capitalizzazione di mercato
166.08B
Categoria di capitalizzazione di mercato
Large-cap
Descrizione
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Dipendenti
16639
Relazioni con gli investitori
-
AD
Paese
Denmark
Città
Tipo di azioni
-
Stato CCC
-
Frequenza dei dividendi
-
EVENTI E PRESENTAZIONI
EventiPresentazioni
Loading...
CAPIRE IL BUSINESS
Loading...
NOTIZIE SULL'AZIENDA
Tutte le notizieComunicati stampa
Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2023/24 was approved.Distribution of ye...
5 dicembre 2024
The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area. Revenue from the core Skin Care business amounted t...
4 dicembre 2024
On 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD)1 policy regarding skin substitute grafts/cellular and tissue-based produc...
14 novembre 2024
The Annual General Meeting of Coloplast A/S will be held onThursday, 5 December 2024 at 3:30 pm CETat the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk...
12 novembre 2024
Coloplast AS (CLPBF) reports robust financial performance with 8% organic growth and strategic product launches, despite facing supply disruptions and competitive pressures.
6 novembre 2024
Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24 FY 2023/24 organic growth of 8% and 27% EBIT margin1. Reported revenue in DKK grew 10% to DKK 27,030 million. Organic growth rates b...
5 novembre 2024
2023/24 Announcement of full-year financial results 1 October 2023 - 30 September 2024 Coloplast delivered Q4 organic growth of 8% and an EBIT margin1 of 26%, which was negatively impacted by extraord...
5 novembre 2024
Coloplast expands Executive Leadership Team Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect. “We have entered the final year of...
5 novembre 2024
Earnings preview of key companies reporting this week and what to look out for.
1 novembre 2024
Tuesday, 5 November 2024 at 11.00 – 12.00 CETIn connection with the publication of Coloplast's interim financial results for FY 2023/24 the company will host a conference call to present the financial...
21 ottobre 2024
Pagina successiva